drugset / Trial / NCT05394350
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study will evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-1088 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors who have not responded to conventional therapy. The effect of MK-1088 on tumor size will also be examined.
Timeline
- Start
- 2022-07-07
- Primary completion
- 2023-09-07
- Completion
- 2023-09-07
Outcome
Outcome not reported
Stopped (Business): “Business Reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-1088 | Unknown | 100 mg | Oral |
| Subject | MK-1088 | Unknown | 200 mg | Oral |
| Subject | MK-1088 | Unknown | 400 mg | Oral |
| Subject | MK-1088 | Unknown | 600 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |